Disease Prevention and Alleviation by Human Myoblast Transplantation

The document discussed the potential of Human Myoblast Transplantation (HMGT/MTT) for treating genetic diseases, including hereditary muscle degeneration, heart disease, and Type II diabetes. HMGT/MTT involved transplanting normal myoblasts into genetically abnormal muscles, allowing natural cell fusion to repair genetic defects. Clinical trials with over 580 patients demonstrated significant improvements in conditions like Duchenne Muscular Dystrophy, heart disease, and Type II diabetes, with minimal immunogenicity and promising long-term outcomes. The therapy also showed potential in enhancing blood capillary growth, which could treat myocardial infarction, impotence, and baldness, highlighting its broad applications in improving quality of life and extending life expectancy.